Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Exploring CBD Vollspektrum ?l and its Benefits: A Comprehensive Guide
-
AB „Grigeo Group“ plans to take over the management of UAB „Grigeo Recycling“
-
Mowi ASA (OSE: MOWI): Share option scheme for senior executives and allocation of options 2024
-
Arendals Fossekompani to build new production facility for Kitron Arendal
-
Gaming Innovation Group signs platform agreement to expand Ontario market footprint
-
Liven AS 2024 financial calendar
-
Renewal of lease contract with Viru Keskus
-
Tineco Launches the 3rd Edition of the Trade-Up Campaign
-
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
-
Alligator Bioscience to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024
-
IDEX Biometrics secures repeat order for IDEX Access from AuthenTrend for new markets
-
Cabka announces 1 August 2024 EGM Agenda
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 20
-
iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials
-
PetroTal Announces Voting Results of Shareholders' Meeting
-
CDN Maverick and NOA Lithium Amend the Nevasca Property Agreement
-
OncoBeta introduces Rhenium-SCT for non-melanoma skin cancer patients at Hospital Universitario 12 de Octubre
-
Taking on World's Extreme Heat with Cooling Technology from Japan: Liberta, Sumitomo Chemical and Utax Jointly Develop Innovative Cooling Wear
-
Lupus Research Alliance Awards Lupus Insight Prize to Two Trailblazers in CAR T Cell Therapy
-
Research at Breda University of Applied Sciences: Don't fall for the vacation paradox
-
My Talking Hank: Islands Sets to Transform Virtual Pet Gaming on July 4th
-
UMC Launches Most Advanced 22nm eHV Platform to Power Next-Generation Smartphone Displays
-
PureTech Announces Change of Board Role
-
INTRESO Highlights Sustainable Alternatives as EU Considers a Ban on Sulfuryl Fluoride
-
bit.bio Launches ioAstrocytes, Advancing How Scientists Can Model the Human Brain
-
Yellowstone Biosciences launches with £16.5 million to pioneer soluble bispecific TCR-based therapies for cancer
-
Fintech & Payment Innovators Invited to Enter Juniper Research’s Future Digital Awards 2024
-
GIST Impact, a leading impact data and analytics provider, receives investment from UBS Next
-
Topdanmark shareholder 1832 Asset Management intends to accept Sampo’s public exchange offer
-
AMG Critical Materials Acquires a Strategic Stake in Savannah Resources
-
TGS and PGS - key dates for completion of merger
-
Irish Residential Properties Sub-Fund 1: Form 8.3 - Irish Residential Properties REIT PLC
-
Transaction in Own Shares
-
NBPE Announces May Monthly NAV Estimate
-
freebeat and Boston Celtics: The Collaborative Power Behind Championship Victory
-
Danone opens the next chapter of its Renew strategy ; Projecting the company into the future of Health and Nutrition
-
Invitation - presentation of Husqvarna Group's report for the second quarter 2024
-
Global NEVS Launches a Unified Model Standard to Enhance Market Insights and Decision Making
-
Envision Energy Launches Advanced 5 MWh Container Battery Energy Storage System with Industry-Leading Safety Standards
-
More Economical, More Space, More Power - GAC EMZOOM Redefining Innovation on Global SUV Market
-
Vallourec extends its contract with the National Oil Company of Abu Dhabi and wins a new order
-
Sensorion Announces Upcoming Presentation of Promising SENS-401 Results at the Next International Conference on Cochlear Implants and Other Implantable Technologies
-
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
-
BGHL (GBP): NAV(s)
-
BGHL (EUR): NAV(s)
-
Sampo plc’s share buybacks 19 June 2024
-
OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)
-
Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million
-
Cantargia presents Phase 2 Clinical Data in Pancreatic Cancer with Nadunolimab at ESMO Gastrointestinal Cancer Congress 2024
-
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
